Back to Search Start Over

Atrial fibrillation screen, management, and guideline-recommended therapy in the rural primary care setting: A cross-sectional study and cost-effectiveness analysis of ehealth tools to support all stages of screening

Authors :
Orchard, J
Li, J
Freedman, B
Webster, R ; https://orcid.org/0000-0002-5136-1098
Salkeld, G
Hespe, C
Gallagher, R
Patel, A ; https://orcid.org/0000-0003-3825-4092
Kamel, B ; https://orcid.org/0000-0002-7993-8776
Neubeck, L
Lowres, N
Orchard, J
Li, J
Freedman, B
Webster, R ; https://orcid.org/0000-0002-5136-1098
Salkeld, G
Hespe, C
Gallagher, R
Patel, A ; https://orcid.org/0000-0003-3825-4092
Kamel, B ; https://orcid.org/0000-0002-7993-8776
Neubeck, L
Lowres, N
Source :
urn:ISSN:2047-9980; Journal of the American Heart Association, 9, 18, e017080
Publication Year :
2020

Abstract

BACKGROUND: Internationally, most atrial fibrillation (AF) management guidelines recommend opportunistic screening for AF in people ≥65 years of age and oral anticoagulant treatment for those at high stroke risk (CHA₂DS₂-VA≥2). However, gaps remain in screening and treatment. METHODS AND RESULTS: General practitioners/nurses at practices in rural Australia (n=8) screened eligible patients (≥65 years of age without AF) using a smartphone ECG during practice visits. eHealth tools included electronic prompts, guideline-based electronic decision support, and regular data reports. Clinical audit tools extracted de-identified data. Results were compared with an earlier study in metropolitan practices (n=8) and nonrandomized control practices (n=69). Cost-effectiveness analysis compared population-based screening with no screening and included screening, treatment, and hospitalization costs for stroke and serious bleeding events. Patients (n=3103, 34%) were screened (mean age, 75.1±6.8 years; 47% men) and 36 (1.2%) new AF cases were confirmed (mean age, 77.0 years; 64% men; mean CHA₂DS₂-VA, 3.2). Oral anticoagulant treatment rates for patients with CHA₂DS₂-VA≥2 were 82% (screen detected) versus 74% (preexisting AF)(P=NS), similar to metropolitan and nonrandomized control practices. The incremental cost-effectiveness ratio for population-based screening was AU$16 578 per quality-adjusted life year gained and AU$84 383 per stroke prevented compared with no screening. National implementation would prevent 147 strokes per year. Increasing the proportion screened to 75% would prevent 177 additional strokes per year. CONCLUSIONS: An AF screening program in rural practices, supported by eHealth tools, screened 34% of eligible patients and was cost-effective. Oral anticoagulant treatment rates were relatively high at baseline, trending upward during the study. Increasing the proportion screened would prevent many more strokes with minimal incremental cost-effectiveness ratio chang

Details

Database :
OAIster
Journal :
urn:ISSN:2047-9980; Journal of the American Heart Association, 9, 18, e017080
Notes :
application/pdf
Publication Type :
Electronic Resource
Accession number :
edsoai.on1199890543
Document Type :
Electronic Resource